The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
And don't forget that Randox had to recall 750,000 of their tests because of fears they would be a danger to the public. This was in July 2020. Didn't stop them getting more repeat business from this corrupt government.
Exmex. You would think the DHSC would have done stringent testing on any products they were spending £100M+ plus on before rolling them out to be used by the public.
Even just follow their own advice from April 2020.
"Accuracy and reliability of tests: as with everything we are doing to tackle
coronavirus, we need to be led by the science. An unreliable test is worse than no
test. We need to ensure that all the tests we use are validated, reliable and
provide an accurate result. We also need to understand the quality of new tests
such as the antibody test before we start using them in order to avoid putting
people at risk by suggesting they are no longer susceptible to coronavirus. We are
working with a number of companies to evaluate tests and this validation is
ongoing - but the science is new and uncertain. This shows the importance of
having a rigorous process in place and checking every step for accuracy and
reliability."
https://assets.publishing.service.gov.uk/media/5e888f05e90e0707799498b3/coronavirus-covid-19-testing-strategy.pdf
Are you saying that the exsig direct product wouldn't detect the covid strains in the autumn of 2020? The company also supplied Winter Plex as part of the contract. Is it the same for that?
"COVID evolved to hide from exsig"
Not sure I agree with that statement Gizmo.
The company still sell it as part of their Covid test portfolio.
It was approved in July 2022 under the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals). A full 2 years and more after the dispute was announced. Must have passed some robust sampling to have passed that.
WHO & FDA both included it on their lists of approved products.
Assume it's just the official record of the judges decision (Mrs Justice Jefford) dismissing the application by the Department of Health and Social Care ("DHSC") for summary judgment.
It's the 8th Order approved so far.
We've finally found the culprit
Well we all saw that coming, maybe not the size though. 400m new shares. Add to the 140m existing shares. I'm sure they only had around 60m shares in issue a few years ago. Absolutely stinker.
Agree B2. The DHSC have tried their best to intimidate Novacyt into backing down with an eye on negotiating a settlement. They are on the ropes and took a wild swing with their attempt to get a quick fire judgment.
They've inflated their claim by adding over £1.3m worth of q16's to it. We know these instruments aren't at fault. They must have had a use for them as they also owe the company just shy of £50m in PROmate supplied.
Has anyone seen any documents from the supposed TVG reports highlighting exsigs poor performance? If so I'd like to see a copy. I've seen various independent reports over the years on exsig and other covid related products and the performance is generally in the high 90's %wise. So their claim came as a real surprise. Obviously they weren't doing it right.
Wilson. Technically LR doesn't become CEO till May 1st however the wording of the rns intimates change has already happened.
JM being the careful man he is probably took it home & stuffed it under his mattress
No it clearly states the company will recover outstanding amounts plus interest.
Ssshh! You might scare it!
Thanks for clarifying that Kaeran.
Not the legal bit just the woodwork.
HC I would think it is less than that.
PI looks like you've done some research. Can you confirm the total revs that those other 4 Covid test companies generarated from sales of covid tests?
This Cambridge Uni article was published a week after the company notified the markets of the DHSC dispute.
No problems here with PrimerDesign products either. 3m tests in colab with the uni, AZ & GSK
https://www.cam.ac.uk/news/cambridge-covid-19-test-centre-has-processed-more-than-3-million-tests
Hundreds of volunteers from across the three organisations, including researchers from the University, were among staff who worked tirelessly during the Centre’s first phase to scale up the diagnostic process at an unprecedented speed. Since then, along with new collaborations with Primerdesign, part of the international diagnostics company Novacyt, and Charles River Laboratories, in Phase 2, the focus has been on further optimising the high-throughput testing using the world-class skills, knowledge and exceptional research made available through the partnership.
UKHSA Document.
https://assets.publishing.service.gov.uk/media/64464e26529eda000c3b02c0/Testing_in_the_UK_during_the_SARS-1.pdf
PCR testing for SARS-CoV-2 in the UK during the COVID-19 pandemic
Use of PCR in the National Testing Programme
April 2023
" Mass testing for SARS-CoV-2 in the UK was initially through polymerase chain reaction
(PCR) testing, with alternative nucleic amplification test methods introduced later. The
development of rapid tests for virus proteins (‘antigens’) in the form of a lateral flow allowed a
further increase in capacity for population-based testing for the virus around November 2020."
"Three of the laboratories (MAN, MK, GLA) ran the same assay (Thermofisher Taqpath) and one
(CAM) ran an alternative assay (Primerdesign). Using the same specimens (with the same
quantities of virus) the different Ct values produced by 2 different PCR assays is clearly
illustrated in Figure 6.
Each laboratory tested 3 replicates of each dilution of the standards panel, and mean Ct values
are shown for each laboratory. All laboratories detected targets in each of the 3 replicates down
to the sample indicated by the dotted red line. This is equivalent to 2.7log10dcopies/mL or
500dcopies/mL (viral RNA was detectable below this threshold in all 3 laboratories using
Taqpath, but not for all 3 replicates). The Primerdesign assay reports much higher Ct values at
each concentration than the assay used in the other 3 laboratories."
"The Primerdesign assay reported much higher Ct values than the Thermofisher assay at each concentration of the virus.
This does not mean the sensitivity or dynamic range of the Primerdesign assay is inferior to the
Thermofisher assay, it merely reflects a different design approach by the assay manufacturer."
Nothing negative about PrimerDesign products.
They were still purchasing products during 2022 to use with the Q16, which they also added to their claim. The tech either worked or it didn't. They certainly took their time in deciding they didn't like it or need it. Decided cheaper, less accurate LFT's were the way forward to make it look like they were doing something.
Department of Health and Social Care UK Health Security Agency 5/13/2022 Laboratory Consumables Testing PRIMERDESIGN LTD 0000316556 298368.00 PROmate Assay Q16
Big Dumping?
Theres only been 50k of shares traded in UK today
NIPT/DNAflc: AT THE EYLAU-UNILABS LABORATORY
At the Eylau Unilabs laboratory, our choice fell on an MPS technique from the company Yourgene: the IONA test. The analysis is carried out on a very high throughput sequencer. This technique has CE-IVD marking for all stages of the process and for patients followed in ART.
The Eylau-Unilabs Neuilly laboratory is equipped with a fully automated platform, located in premises reserved for prenatal genetics activity, in accordance with the quality criteria of the Biomedicine Agency.
https://my-unilabs.fr/articles/blog-sante/dpni-ad-nflc?c=%23C4396D